Skip to main content

Table 6 Patients’ characteristics and baseline parameters with and without cultivated multidrug-resistant organisms

From: The role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses

Characteristics

Patient with MDRO isolates (n = 21)

Patient without MDRO isolates (n = 52)a

P

Age, y

61 (52–71)

63 (52–73)

0.812

Duration of hospitalization, days

20 (13–37)

19 (10–32)

0.425

Biliary cause of PLA, n (%)

16 (76.2)

32 (61.5)

0.284

Malignancy, n (%)

7 (33.3)

22 (42.3)

0.600

Liver cirrhosis, n (%)

4 (19.0)

8 (15.4)

0.734

Diabetes mellitus, n (%)

4 (19.0)

16 (30.8)

0.392

Cholangitis, n (%)

14 (66.7)

22 (42.3)

0.074

Intake of immunosuppressants, n (%)

6 (28.6)

14 (26.9)

1.000

Intake of proton-pump inhibitors, n (%)

17 (81.0)

39 (75.0)

0.762

Previous known MDRO, n (%)

12 (57.1)

3 (5.8)

<0.0001

Previous admission <3 month, n (%)

20 (95.2)

44 (84.6)

0.432

Previous ICU admission <3 month, n (%)

7 (33.3)

10 (19.2)

0.229

Previous surgical/endoscopic Intervention

 Previous endoscopic Intervention, n (%)

17 (81.0)

33 (63.5)

0.174

 Previous ERCP/PTCD, n (%)

17 (81.0)

28 (53.8)

0.036

 ERCP/PTCD <3 month, n (%)

17 (81.0)

25 (48.1)

0.017

 Laid-in biliary stent, n (%)

14 (66.7)

22 (42.3)

0.074

 History of abdominal surgery, n (%)

15 (71.4)

29 (55.8)

0.293

 Abdominal surgery <6 month, n (%)

9 (42.9)

18 (34.6)

0.023

Prior antibiotic therapyb

 Any antibiotic therapy, n (%)

15 (78.9)

26 (55.3)

0.096

 Glycopeptide based, n (%)

7 (36.8)

4 (8,5)

0.010

 Carbapenem based, n (%)

10 (52.6)

12 (25.5)

0.046

 Piperacillin/Tazobactam, n (%)

4 (21.1)

4 (8.5)

0.213

Laboratory results

 C-reactive protein (mg/dl)

9.78 (6.9–15.2)

11.28 (8.6–20.8)

0.453

 White blood count (/nl)

10.4 (7.5–15.6)

11.6 (7.7–16.4)

0.943

 International normalized ratio

1.2 (1.1–1.4)

1.3 (1.2–1.4)

0.165

 Creatinine (mg/dl)

0.91 (0.62–1.20)

0.79 (0.58–0.95)

0.352

 Albumin (g/dl)

2.6 (2.2–2.9)

2.8 (2.2–3.1)

0.500

 Aspartate aminotransferase (U/l)

69 (35–106)

42 (24–113)

0.328

 Alanine aminotransferase (U/l)

40 (25–64)

34 (18–84)

0.933

 γ-Glutamyltransferase (U/l)

281 (136–441)

199 (93–458)

0.371

 Alkaline phosphatase (UI/l)

282 (196–401)

226 (133–425)

0.247

 Bilirubin (mg/dl)

1.0 (0.5–4.9)

1.0 (0.6–3.4)

0.981

  1. Data are presented as media (IQR) unless otherwise indicated
  2. Abbreviations: ERCP endoscopic retrograde cholangiopancreatography, PTCD percutaneous transhepatic cholangiography and drainage
  3. aPatients without resistance profile of bacterial isolates or without bacterial isolates were excluded
  4. bDefined as ≥72 h antibiotic therapy before given cultures were attempted, overall n = 66